Back to Search Start Over

Perinatal Screening for Group B Streptococci: Cost-Benefit Analysis of Rapid Polymerase Chain Reaction.

Authors :
Haberland, Corinna A.
Benitz, William E.
Sanders, Gillian D.
Pietzsch, Jan Benjamin
Yamada, Sanae
Nguyen, Lan
Garber, Alan M.
Source :
Pediatrics. Sep2002, Vol. 110 Issue 3, p471. 10p. 1 Diagram, 4 Graphs.
Publication Year :
2002

Abstract

ABSTRACT. Objective. To evaluate the costs and benefits of a group B streptococci screening strategy using a new, rapid polymerase chain reaction test in a hypothetical cohort of expectant mothers in the United States. Methods. Design. Cost-benefit analysis using the human capital method. We developed a decision model to analyze the costs and benefits of a hypothetical group B streptococci screening strategy using a new, rapid polymerase chain reaction test as compared with the currently recommended group B streptococci screening guidelines--prenatal culture performed at 35 to 37 weeks or risk-factor-based strategy with subsequent intrapartum treatment of the expectant mothers with antibiotics to prevent early-onset group B streptococcal infections in their infants. Participants. A hypothetical cohort of pregnant women and their newborns. Interventions. Screening strategies for group B streptococci using the new polymerase chain reaction technique, the 35- to 37-week culture, or maternal risk factors. Outcome Measures. Infant infections averted, infant deaths, infant disabilities, costs, and societal benefits of healthy infants. Results. A screening strategy using the new polymerase chain reaction test generates a net benefit of $7 per birth when compared with the maternal risk-factor strategy. For every 1 million births, 80 700 more women would receive antibiotics, 884 fewer infants would become infected with early-onset group B streptococci, and 23 infants would be saved from death or disability. The polymerase chain reaction-based strategy generates a net benefit of $6 per birth when compared with the 35- to 37-week prenatal culture strategy and results in fewer maternal courses of antibiotics (64 080 per million births), fewer perinatal infections with early-onset group B streptococci (218/million), and a reduction in 6 infant deaths and severe infant disability per million births. The benefits hold over a wide range of assumptions regarding key... [ABSTRACT FROM AUTHOR]

Details

Language :
English
ISSN :
00314005
Volume :
110
Issue :
3
Database :
Academic Search Index
Journal :
Pediatrics
Publication Type :
Academic Journal
Accession number :
7312113
Full Text :
https://doi.org/10.1542/peds.110.3.471